Optimal timing of antimicrobial prophylaxis prior to colorectal cancer surgery A retrospective analysis among 531 patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030355

Enrollment

531

Registered

2022-10-05

Start date

2022-10-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C18 C20

Interventions

Group 1: cefuroxime/metronidazole, piperacillin/tazobactam or mezlocillin/sulbactam before, during operation

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Electronic files of people who had surgery for colorectal cancer and received cefuroxime/metronidazole, piperacillin/tazobactam, or mezlocillin/sulbactam were analyzed

Exclusion criteria

Exclusion criteria: Patients, who received neither cefuroxime/metronidazole nor piperacillin/tazobactam or mezlocillin/sulbactam were excluded.

Design outcomes

Primary

Measure	Time frame
Rate SSI postoperatively within 30 days	—

Secondary

Measure	Time frame
Rate SSO, SSOPI postoperatively within 30 days	—

Countries

Germany

Contacts

Public ContactChristoph Paasch

Oberarzt in der Klinik für Allgemein- und ViszeralchirurgieUniversitätsklinikum Brandenburg an der HavelMedizinische Hochschule Brandenburg

paasch.mhb@klinikum-brandenburg.de004933811249

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026